EE05514B1 - L karnitiini v i alkanol L karnitiinide estrid katioonsete lipiididena farmakoloogiliselt aktiivsete komponentidena intratsellulaarseks kohaletoimetamiseks - Google Patents

L karnitiini v i alkanol L karnitiinide estrid katioonsete lipiididena farmakoloogiliselt aktiivsete komponentidena intratsellulaarseks kohaletoimetamiseks

Info

Publication number
EE05514B1
EE05514B1 EEP200100518A EEP200100518A EE05514B1 EE 05514 B1 EE05514 B1 EE 05514B1 EE P200100518 A EEP200100518 A EE P200100518A EE P200100518 A EEP200100518 A EE P200100518A EE 05514 B1 EE05514 B1 EE 05514B1
Authority
EE
Estonia
Prior art keywords
carnitines
carnitine
alkanoyl
esters
pharmacologically active
Prior art date
Application number
EEP200100518A
Other languages
English (en)
Estonian (et)
Inventor
Claudio@Pisano
Maria@Ornella@Tinti
Mos�@Santaniello
Luciana@Critelli
Giovanni@Salvatori
Original Assignee
Sigma@Tau@Industrie@Farmaceutiche@Riunite@S@p@A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma@Tau@Industrie@Farmaceutiche@Riunite@S@p@A filed Critical Sigma@Tau@Industrie@Farmaceutiche@Riunite@S@p@A
Priority to EEP201100028A priority Critical patent/EE05719B1/et
Publication of EE200100518A publication Critical patent/EE200100518A/xx
Publication of EE05514B1 publication Critical patent/EE05514B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200100518A 1999-04-13 2000-04-11 L karnitiini v i alkanol L karnitiinide estrid katioonsete lipiididena farmakoloogiliselt aktiivsete komponentidena intratsellulaarseks kohaletoimetamiseks EE05514B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP201100028A EE05719B1 (et) 1999-04-13 2000-04-11 L-karnitiini või alkanoüül-L-karnitiinide estrite kasutamine katioonsete lipiididena farmakoloogiliselt aktiivsete komponentide intratsellulaarseks kohaletoimetamiseks

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines

Publications (2)

Publication Number Publication Date
EE200100518A EE200100518A (et) 2002-12-16
EE05514B1 true EE05514B1 (et) 2012-02-15

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP201100028A EE05719B1 (et) 1999-04-13 2000-04-11 L-karnitiini või alkanoüül-L-karnitiinide estrite kasutamine katioonsete lipiididena farmakoloogiliselt aktiivsete komponentide intratsellulaarseks kohaletoimetamiseks
EEP200100518A EE05514B1 (et) 1999-04-13 2000-04-11 L karnitiini v i alkanol L karnitiinide estrid katioonsete lipiididena farmakoloogiliselt aktiivsete komponentidena intratsellulaarseks kohaletoimetamiseks

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP201100028A EE05719B1 (et) 1999-04-13 2000-04-11 L-karnitiini või alkanoüül-L-karnitiinide estrite kasutamine katioonsete lipiididena farmakoloogiliselt aktiivsete komponentide intratsellulaarseks kohaletoimetamiseks

Country Status (34)

Country Link
US (4) US6797281B1 (xx)
EP (3) EP1435232A1 (xx)
JP (2) JP4703855B2 (xx)
KR (2) KR100684378B1 (xx)
CN (2) CN100402017C (xx)
AT (2) ATE286873T1 (xx)
AU (2) AU776301B2 (xx)
BG (3) BG65501B1 (xx)
BR (2) BRPI0017460B1 (xx)
CA (2) CA2370143C (xx)
CZ (1) CZ302628B6 (xx)
DE (2) DE60017388T2 (xx)
DK (2) DK1426044T3 (xx)
EA (2) EA004459B1 (xx)
EE (2) EE05719B1 (xx)
ES (2) ES2234591T3 (xx)
HK (2) HK1045145B (xx)
HR (1) HRP20010740B1 (xx)
HU (1) HU229366B1 (xx)
IL (4) IL145765A0 (xx)
IS (2) IS2476B (xx)
IT (1) IT1306129B1 (xx)
ME (2) MEP24008A (xx)
MX (1) MXPA01010359A (xx)
NO (2) NO327742B1 (xx)
NZ (2) NZ528874A (xx)
PL (2) PL204418B1 (xx)
PT (2) PT1426044E (xx)
RS (3) RS20090448A (xx)
SI (2) SI1183228T1 (xx)
SK (2) SK287253B6 (xx)
TR (2) TR200202358T2 (xx)
WO (1) WO2000061543A2 (xx)
ZA (1) ZA200109291B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
PT2286795T (pt) * 2002-06-26 2017-01-27 Syncore Biotechnology Co Ltd Processo de produção de uma preparação lipossomal catiónica que compreende um composto lipófilo
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
EP1868571A4 (en) * 2005-03-02 2011-10-26 Univ Northeastern MITOCHONDRIOTROPIC PHOSPHOLIPIDE VESICLES
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CA2617873A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
TW200800195A (en) * 2005-08-10 2008-01-01 Novartis Ag Organic compounds
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
US20100166843A1 (en) * 2007-02-01 2010-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
US20100104625A1 (en) * 2007-02-16 2010-04-29 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
WO2009114763A2 (en) 2008-03-13 2009-09-17 Perkinelmer Las, Inc. Enzymatic substrates for multiple detection systems
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140274798A1 (en) 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and methods relating to lysosomal storage disorders
CN109069440A (zh) 2016-03-02 2018-12-21 得克萨斯州大学系统董事会 用于免疫治疗的激活sting的纳米疫苗
WO2018226854A2 (en) * 2017-06-06 2018-12-13 Wayne State University Antifouling polymer coatings and reverse coating method
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
AU660417B2 (en) * 1990-06-15 1995-06-29 University Of North Carolina At Chapel Hill, The Ether lipid-nucleoside covalent conjugates
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
NO20085413L (no) 2001-10-12
US6797281B1 (en) 2004-09-28
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
NO336949B1 (no) 2015-11-30
DK1426044T3 (da) 2006-06-12
ES2234591T3 (es) 2005-07-01
EA200101076A1 (ru) 2002-04-25
CA2650202C (en) 2012-12-11
PT1183228E (pt) 2005-04-29
IL175366A (en) 2010-12-30
HK1092732A1 (en) 2007-02-16
IS6095A (is) 2001-09-28
HUP0201446A2 (en) 2002-08-28
DE60017388T2 (de) 2006-03-30
SK287253B6 (sk) 2010-04-07
HU229366B1 (en) 2013-11-28
CA2370143C (en) 2011-06-21
JP2002541238A (ja) 2002-12-03
DK1183228T3 (da) 2005-05-17
DE60025961D1 (de) 2006-04-20
EP1426044B1 (en) 2006-02-08
SI1183228T1 (en) 2005-04-30
EA004459B1 (ru) 2004-04-29
HRP20010740B1 (en) 2005-08-31
ITRM990220A1 (it) 2000-10-13
BG65312B1 (bg) 2008-01-31
RS20090448A (xx) 2010-06-30
TR200202358T2 (tr) 2002-12-23
ZA200109291B (en) 2002-08-16
HK1045145B (zh) 2006-01-27
IS8719A (is) 2008-03-07
CZ302628B6 (cs) 2011-08-10
EA200300745A1 (ru) 2003-12-25
US20040186175A1 (en) 2004-09-23
NO20014985D0 (no) 2001-10-12
EE200100518A (et) 2002-12-16
AU4312300A (en) 2000-11-14
BR0009765B1 (pt) 2013-11-05
ES2258688T3 (es) 2006-09-01
CN100402017C (zh) 2008-07-16
AU776301B2 (en) 2004-09-02
CN1823731A (zh) 2006-08-30
BR0009765A (pt) 2002-01-02
JP4703855B2 (ja) 2011-06-15
NO327742B1 (no) 2009-09-14
CN1263730C (zh) 2006-07-12
IL145765A (en) 2007-07-04
EP1183228A2 (en) 2002-03-06
IS2476B (is) 2008-12-15
AU2004224958A1 (en) 2004-11-25
KR20010113794A (ko) 2001-12-28
NZ528874A (en) 2005-09-30
US7585519B2 (en) 2009-09-08
HK1045145A1 (en) 2002-11-15
EE201100028A (et) 2011-08-15
PL211710B1 (pl) 2012-06-29
BG65501B1 (bg) 2008-10-31
CZ20013617A3 (cs) 2002-02-13
KR100798499B1 (ko) 2008-01-28
HRP20010740A2 (en) 2002-10-31
MEP24008A (en) 2010-06-10
WO2000061543A3 (en) 2001-01-11
BRPI0017460B1 (pt) 2016-04-19
CA2370143A1 (en) 2000-10-19
CA2650202A1 (en) 2000-10-19
EA006021B1 (ru) 2005-08-25
IL145765A0 (en) 2002-07-25
SK288246B6 (sk) 2015-03-03
US20050079209A1 (en) 2005-04-14
EE05719B1 (et) 2014-08-15
IS2539B (is) 2009-09-15
DE60017388D1 (de) 2005-02-17
DE60025961T2 (de) 2006-08-17
US20070190128A1 (en) 2007-08-16
SI1426044T1 (sl) 2006-04-30
EP1435232A1 (en) 2004-07-07
IL175366A0 (en) 2006-09-05
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
CN1359370A (zh) 2002-07-17
AU2004224958B2 (en) 2007-11-22
BG105971A (en) 2002-08-30
BG109876A (en) 2008-02-29
PL204418B1 (pl) 2010-01-29
EP1183228B1 (en) 2005-01-12
JP2011042657A (ja) 2011-03-03
ME00113B (me) 2010-10-10
ATE286873T1 (de) 2005-01-15
JP5420507B2 (ja) 2014-02-19
PT1426044E (pt) 2006-06-30
KR20060113799A (ko) 2006-11-02
US7629003B2 (en) 2009-12-08
HUP0201446A3 (en) 2002-11-28
IT1306129B1 (it) 2001-05-30
NO20014985L (no) 2001-10-12
MXPA01010359A (es) 2002-05-06
SK14312001A3 (sk) 2002-02-05
EP1426044A1 (en) 2004-06-09
RS50911B (sr) 2010-08-31
KR100684378B1 (ko) 2007-02-20
YU70201A (sh) 2004-07-15
TR200102941T2 (tr) 2002-05-21
ATE317257T1 (de) 2006-02-15
IL185486A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
HK1092732A1 (en) Esters of l-carnitine or alkanaoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
SE9902742D0 (sv) New pharmaceutical formultion
PT1075461E (pt) Esteres perfluorinados de l-carnitina de alcanoilo para a preparacao de lipidoscationicos para a libertacao intracelular de compostos farmacologicamente activos

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20170411